Agile And Differentiated, AlphaMab Riding High In China Biotech Boom
This article was originally published in PharmAsia News
AlphaMab is attracting attention as the Suzhou-based biotech has filed China's first PD-L1 antibody, giving it a lead over larger and multinational competitors. The venture’s winning strategy lies in staying ahead of the curve, CEO Xu Ting told PharmAsia News in an exclusive interview.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.
China is set to grant priority reviews to major biologics from Roche, the first CAR-T therapy from Wuxi Juno, and breakthrough therapy designation to a pediatric respiratory antiviral from ArkBio.